{"prompt": "['Alliance A221701', '15.0 References', '1.', 'Rugo HS, Pritchard KI, Gnant M, et al: Incidence and time course of everolimus-related', 'adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer:', 'insights from BOLERO-2. Ann Oncol 25:808-15, 2014', '2.', 'Rugo HS, Hortobagyi GN, Yao J, et al: Meta-analysis of stomatitis in clinical studies of', 'everolimus: incidence and relationship with efficacy. Ann Oncol 27:519-25, 2016', '3.', 'Altenburg A, El-Haj N, Micheli C, et al: The treatment of chronic recurrent oral aphthous', 'ulcers. Dtsch Arztebl Int 111:665-73, 2014', '4.', 'Femiano F, Lanza A, Buonaiuto C, et al: Guidelines for diagnosis and management of', 'aphthous stomatitis. Pediatr Infect Dis J 26:728-32, 2007', '5.', 'Fani MM, Ebrahimi H, Pourshahidi S, et al: Comparing the Effect of Phenytoin Syrup', \"and Triamcinolone Acetonide Ointment on Aphthous Ulcers in Patients with Behcet's Syndrome. Iran\", 'Red Crescent Med J 14:75-8, 2012', '6.', 'Pakfetrat A, Mansourian A, Momen-Heravi et al: Comparison of colchicine versus', 'prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial. Clin Invest Med', '33:E189-95, 2010', '7.', 'Femiano F, Buonaiuto C, Gombos F, et al: Pilot study on recurrent aphthous stomatitis', '(RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic', 'prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral Surg Oral Med', 'Oral Pathol Oral Radiol Endod 109:402-7, 2010', '8.', 'Vincent SD: Chronic mucositis: differential diagnosis and therapeutic management.', 'Compendium 13:600, 602, 604-10, 1992', '9.', 'de Oliveira MA, Martins EMF, Wang Q, et al: Clinical presentation and management of', 'mTOR mhibitor-associated stomatitis. Oral Oncol 47:998-1003, 2011', '10.', 'Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, et al: Oral ulcers in patients with', 'advanced breast cancer receiving everolimus: a case series report on clinical presentation and', 'management. Oral Surg Oral Med Oral Pathol Oral Radiol 16:e110-6,2013', '11. Divers J: Management of stomatitis associated with mTOR inhibitors in hormone', 'receptor-positive/HER2-negative advanced breast cancer: clinical experiences from a single center. 38th', 'Annual Oncology Nurses Society Congress, 2013', '12.', 'Rugo HS, Seneviratne L, Beck JT, et al: Prevention of everolimus/exemestane', '(EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic', 'breast cancer (MBC) using dexamethasone-based mouthwash (MW): Results of the SWISH trial. J Clin', 'Oncol 34, 2016', '13.', 'Jones VL, Jensen LL, McIntyre KJ, et al: Evaluation of miracle mouthwash (MMW) plus', 'hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis:', 'Preliminary results of a randomized phase II study. Cancer Res 76:Abstract nr P1-15-06, 2016', '14. Spring L, Bardia A: SWISH-ing steroids: new standard of care to prevent everolimus-', 'induced oral mucositis? Lancet Oncol 18:564-565, 2017', '15.', 'Sloan J A, Dueck A. Issues for statisticians in conducting analyses and translating results', 'for quality of life end points in clinical trials. J Biopharm Stat 2004;14(1):73-96. PMID: 15027501.', '16.', 'Basch E, Abernethy AP, Mullins CD, et al: Recommendations for incorporating patient-', 'reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol', '30:4249-55, 2012', '17.', 'Atkinson TM, Ryan SJ, Bennett AV, et al: The association between clinician-based', 'common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a', 'systematic review. Support Care Cancer 24:3669-76, 2016', '18.', 'Basch E, Jia X, Heller G, et al: Adverse symptom event reporting by patients VS', 'clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624-32, 2009', '57', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '19.', 'Kottschade LA, Sloan JA, Mazurczak MA, et al: The use of vitamin E for the prevention', 'of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support', 'Care Cancer 19:1769-77, 2011', '20.', 'Moraska AR, Sood A, Dakhil SR, et al: Phase III, randomized, double-blind, placebo-', 'controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer', 'Treatment Group NCCTG-N05C7 trial. J Clin Oncol 28:3673-9, 2010', '21.', \"Basch E, Reeve BB, Mitchell SA, et al: Development of the National Cancer Institute's\", 'patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).', 'J Natl Cancer Inst 106, 2014', '22.', 'Bennett AV, Dueck AC, Mitchell SA, et al: Mode equivalence and acceptability of tablet', 'computer-, interactive voice response system-, and paper-based administration of the U.S. National', \"Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse\", 'Events (PRO-CTCAE). Health Qual Life Outcomes 14:24, 2016', '23.', 'Dueck AC, Mendoza TR, Mitchell SA, et al: Validity and Reliability of the US National', \"Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse\", 'Events (PRO-CTCAE). JAMA Oncol 1:1051-9, 2015', '24. Kluetz PG, Chingos DT, Basch EM, et al: Patient-Reported Outcomes in Cancer Clinical', \"Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported\", 'Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc', 'Clin Oncol Educ Book 35:67-73, 2016', '25.', 'Brown P, Clark MM, Atherton P, et al: Will improvement in quality of life (QOL) impact', 'fatigue in patients receiving radiation therapy for advanced cancer? Am J Clin Oncol 29:52-8, 2006', '26.', 'Shahi V, Lapid MI, Kung S, et al: Do age and quality of life of patients with cancer', 'influence quality of life of the caregiver? J Geriatr Oncol 5:331-6, 2014', '27. Singh JA, Locke DE, Satele D, et al: Normative data and clinically significant effect sizes', 'for single-item numerical linear analogue self-assessment (LASA) scales. J Clin Oncol 32:e17619, 2014', '28.', 'Rummans TA, Clark MM, Sloan JA, et al: Impacting quality of life for patients with', 'advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin', 'Oncol 24:635-42, 2006', '29.', 'Sloan, J. A., & Dueck, A. (2004). Issues for statisticians in conducting analyses and', 'translating results for quality of life end points in clinical trials. J Biopharm Stat, 14(1), 73-96.', 'doi: 10.1081/BIP-120028507', '30.', 'Atherton et al. J Pain Symptom Manage. 2015 Oct;50(4):470-9.e9', '31.', 'Sloan et al. Randomized comparison of four tools measuring overall quality of life in', 'patients with advanced cancer. JCO 1998.', '32.', 'Sloan et al Relationship between deficits in overall quality of life and non-small-cell lung', 'cancer survival, JCO 2012', '33.', 'List et al. The Performance Status Scale for Head and Neck Cancer Patients and the', 'Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer.', '1996', '34.', 'Bell ML, King MT, Fairclough DL. Bias in area under the curve for longitudinal clinical', 'trials with missing patient reported outcome data: summary measures versus summary statistics. SAGE', 'Open. Jun 2014;4(2): 1-12. doi:10.1177/2158244014534858', '35.', 'Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK.', 'Responsiveness and minimal important differences for patient reported outcomes - art. no. 70. Health &', 'Quality of Life Outcomes 2006 Sep 27; 4:70.', '36.', 'Sloan JA. Assessing the Minimally Clinically Significant Difference: Scientific', 'Considerations, Challenges and Solutions. Journal of Chronic Obstructive Pulmonary', 'Disease 2005; 2: 57-62', '58', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}